Enanta Pharmaceuticals (NASDAQ:ENTA) Given New $24.00 Price Target at JMP Securities

Enanta Pharmaceuticals (NASDAQ:ENTA) had its target price raised by JMP Securities from $23.00 to $24.00 in a research report report published on Tuesday,Benzinga reports. JMP Securities currently has a market outperform rating on the biotechnology company’s stock.

A number of other analysts have also recently weighed in on ENTA. Wall Street Zen raised shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, February 19th. HC Wainwright reissued a “buy” rating and set a $18.00 price objective on shares of Enanta Pharmaceuticals in a report on Tuesday, February 11th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Enanta Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $18.00.

Enanta Pharmaceuticals Stock Up 14.3%

Shares of NASDAQ:ENTA opened at $7.19 on Tuesday. The firm’s 50 day moving average price is $5.42 and its 200 day moving average price is $6.22. The stock has a market cap of $153.70 million, a price-to-earnings ratio of -1.45 and a beta of 0.81. Enanta Pharmaceuticals has a fifty-two week low of $4.09 and a fifty-two week high of $17.24.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings data on Monday, May 12th. The biotechnology company reported ($1.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.04) by ($0.02). Enanta Pharmaceuticals had a negative return on equity of 75.53% and a negative net margin of 157.57%. The company had revenue of $14.93 million for the quarter, compared to analyst estimates of $15.96 million. On average, equities analysts anticipate that Enanta Pharmaceuticals will post -4.65 EPS for the current year.

Hedge Funds Weigh In On Enanta Pharmaceuticals

A number of hedge funds have recently modified their holdings of the business. Acadian Asset Management LLC grew its position in shares of Enanta Pharmaceuticals by 2.1% during the first quarter. Acadian Asset Management LLC now owns 867,037 shares of the biotechnology company’s stock worth $4,782,000 after acquiring an additional 17,613 shares during the last quarter. Goldman Sachs Group Inc. grew its position in Enanta Pharmaceuticals by 5.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 130,410 shares of the biotechnology company’s stock valued at $720,000 after buying an additional 6,549 shares during the last quarter. Millennium Management LLC increased its stake in Enanta Pharmaceuticals by 50.2% in the 1st quarter. Millennium Management LLC now owns 1,346,932 shares of the biotechnology company’s stock valued at $7,435,000 after buying an additional 449,945 shares during the period. AQR Capital Management LLC increased its stake in Enanta Pharmaceuticals by 674.7% in the 1st quarter. AQR Capital Management LLC now owns 357,109 shares of the biotechnology company’s stock valued at $1,971,000 after buying an additional 311,010 shares during the period. Finally, PDT Partners LLC increased its stake in Enanta Pharmaceuticals by 217.5% in the 1st quarter. PDT Partners LLC now owns 106,200 shares of the biotechnology company’s stock valued at $586,000 after buying an additional 72,751 shares during the period. 94.99% of the stock is currently owned by hedge funds and other institutional investors.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.